These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38778456)

  • 1. Integrating genetic and socioeconomic data to predict the progression of nonalcoholic fatty liver disease.
    Rieman-Klingler MC; Jung J; Tesfai K; Loomba R; Non AL
    Am J Biol Anthropol; 2024 Aug; 184(4):e24979. PubMed ID: 38778456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of
    Elmansoury N; Megahed AA; Kamal A; El-Nikhely N; Labane M; Abdelmageed M; Daly AK; Wahid A
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD.
    Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N
    Clin Transl Gastroenterol; 2021 Sep; 12(9):e00400. PubMed ID: 34506332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
    Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
    Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD.
    Jarasvaraparn C; Vilar-Gomez E; Yates KP; Wilson LA; Neuschwander-Tetri B; Loomba R; Cummings O; Vos M; Xanthakos S; Schwimmer J; Molleston JP; Sanyal A; Tonascia J; Chalasani N
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1024-1036.e2. PubMed ID: 38145725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Mizuno N; Okuda K; Takemura M; Taketani H; Hara T; Umemura A; Nishikawa T; Moriguchi M; Yasui K; Kamaguchi M; Nishioji K; Mochizuki N; Kobayashi M; Mori K; Tanaka S; Matsuura K; Tanaka Y; Itoh Y
    J Gastroenterol; 2018 Mar; 53(3):438-448. PubMed ID: 28744823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARVB and HSD17B13 variants are associated with nonalcoholic fatty liver disease in children.
    Lee KJ; Moon JS; Lim JG; Huh H; Ahn JE; Kim L; Kim NY; Ko JS
    J Gastroenterol Hepatol; 2024 Jun; 39(6):1172-1182. PubMed ID: 38418429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Tanaka S; Mori K; Okanoue T; Itoh Y
    Liver Int; 2020 Jul; 40(7):1686-1692. PubMed ID: 32342668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population.
    Rashu EB; Werge MP; Hetland LE; Thing M; Nabilou P; Kimer N; Junker AE; Jensen AH; Nordestgaard BG; Stender S; Gluud LL
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102389. PubMed ID: 38830575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea.
    Lee SS; Byoun YS; Jeong SH; Woo BH; Jang ES; Kim JW; Kim HY
    Dig Dis Sci; 2014 Dec; 59(12):2967-74. PubMed ID: 25069572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank.
    Walker RW; Belbin GM; Sorokin EP; Van Vleck T; Wojcik GL; Moscati A; Gignoux CR; Cho J; Abul-Husn NS; Nadkarni G; Kenny EE; Loos RJF
    J Hepatol; 2020 Jun; 72(6):1070-1081. PubMed ID: 32145261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linked PNPLA3 polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B.
    Pan Q; Zhang RN; Wang YQ; Zheng RD; Mi YQ; Liu WB; Shen F; Chen GY; Lu JF; Zhu CY; Zhang SY; Chen YM; Sun WL; Fan JG
    World J Gastroenterol; 2015 Jul; 21(28):8605-14. PubMed ID: 26229402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of HSD17B13 and PNPLA3 With Liver Enzymes and Fibrosis in Hispanic/Latino Individuals of Diverse Genetic Ancestries.
    Rutledge SM; Soper ER; Ma N; Pejaver V; Friedman SL; Branch AD; Kenny EE; Belbin GM; Abul-Husn NS
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2578-2587.e11. PubMed ID: 36610497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. American Ancestry Is a Risk Factor for Suspected Nonalcoholic Fatty Liver Disease in Hispanic/Latino Adults.
    Kallwitz ER; Tayo BO; Kuniholm MH; Cai J; Daviglus M; Cooper RS; Cotler SJ
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2301-2309. PubMed ID: 30743004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes.
    Bridi L; Agrawal S; Tesfai K; Madamba E; Bettencourt R; Richards LM; Khera AV; Loomba R; Ajmera V
    Aliment Pharmacol Ther; 2024 Aug; 60(3):369-377. PubMed ID: 38825972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children.
    Lee KJ; Moon JS; Kim NY; Ko JS
    Pediatr Obes; 2022 Feb; 17(2):e12852. PubMed ID: 34490745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort
    Anstee QM; Darlay R; Cockell S; Meroni M; Govaere O; Tiniakos D; Burt AD; Bedossa P; Palmer J; Liu YL; Aithal GP; Allison M; Yki-Järvinen H; Vacca M; Dufour JF; Invernizzi P; Prati D; Ekstedt M; Kechagias S; Francque S; Petta S; Bugianesi E; Clement K; Ratziu V; Schattenberg JM; Valenti L; Day CP; Cordell HJ; Daly AK;
    J Hepatol; 2020 Sep; 73(3):505-515. PubMed ID: 32298765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
    Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY
    World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PNPLA3 is the dominant SNP linked to liver disease severity at time of first referral to a tertiary center.
    Balcar L; Semmler G; Oberkofler H; Zandanell S; Strasser M; Datz L; Niederseer D; Feldman A; Stickel F; Datz C; Paulweber B; Aigner E
    Dig Liver Dis; 2022 Jan; 54(1):84-90. PubMed ID: 34261618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.